

**Astellas at ASCO 2020**  
Presentation Overview

Abstract Title	Abstract Number
<b>Enfortumab Vedotin</b>	
EV-202: A Phase II Study of Enfortumab Vedotin in Patients With Select Previously Treated Locally Advanced or Metastatic Solid Tumors	<a href="#">TPS3647</a>
Study EV-103: New Randomized Cohort Testing Enfortumab Vedotin as Monotherapy or in Combination with Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer	<a href="#">TPS5092</a>
Study EV-103: Durability Results of Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma	<a href="#">5044</a>
<b>Enzalutamide</b>	
Final Overall Survival (OS) From PROSPER: A Phase III, Randomized, Double-Blind, Placebo (PBO)-Controlled Study of Enzalutamide (ENZA) in Men With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)	<a href="#">5515</a>
Efficacy of Enzalutamide (ENZA) + Androgen Deprivation Therapy (ADT) in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses	<a href="#">5547</a>
<b>Gilteritinib</b>	
Long-term Survivors and Gilteritinib Safety Beyond One Year in FLT3-Mutated R/R AML: ADMIRAL Trial Follow Up	<a href="#">7514</a>
<b>Zolbetuximab</b>	
Phase III Study of First-line Zolbetuximab + CAPOX Versus Placebo + CAPOX in Claudin18.2+/HER2-Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: GLOW	<a href="#">TPS4648</a>
Phase II, Open-Label, Randomized Study of First-line Zolbetuximab Plus Gemcitabine and Nab-Paclitaxel (GN) in Claudin 18.2-Positive Metastatic Pancreatic Cancer (mPC)	<a href="#">TPS4667</a>

###